Renaliv
Generic Name
Finerenone
Manufacturer
Acme Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| renaliv 5 mg tablet | ৳ 15.00 | ৳ 150.00 |
Description
Overview of the medicine
Renaliv (Finerenone) is used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Uses & Indications
Dosage
Adults
Initial dose is 10 mg or 20 mg once daily based on eGFR. Maximum recommended dose is 20 mg once daily.
Elderly
No specific dose adjustment is required based on age alone. Monitor renal function and potassium levels.
Renal_impairment
For eGFR 25 to <60 mL/min/1.73m²: Start with 10 mg daily. If eGFR ≥60 mL/min/1.73m²: Start with 20 mg daily. Avoid initiation if eGFR <25 mL/min/1.73m².
How to Take
Take Renaliv orally once daily, with or without food. Swallow the tablet whole with water. Do not crush, chew, or divide.
Mechanism of Action
Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. It blocks overactivation of MRs which contributes to inflammation and fibrosis in the kidneys and heart.
Pharmacokinetics
Onset
Steady-state concentrations are achieved within 2-3 days. Clinical benefits are typically observed over several months of treatment.
Excretion
Approximately 80% is excreted via feces (mainly as metabolites) and about 20% via urine (mainly as metabolites).
Half life
The terminal elimination half-life is approximately 2-3 hours.
Absorption
Oral bioavailability is approximately 44%. Peak plasma concentrations are reached within 0.5-1.25 hours.
Metabolism
Primarily metabolized by CYP3A4 (approximately 90%) and to a lesser extent by CYP2C8 (approximately 10%).
Side Effects
Contraindications
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir)
- Adrenal insufficiency
Drug Interactions
Strong CYP3A4 Inducers
Avoid concomitant use due to significantly decreased finerenone exposure, reducing efficacy.
Strong CYP3A4 Inhibitors
Concomitant use is contraindicated due to significantly increased finerenone exposure and risk of hyperkalemia.
Moderate CYP3A4 Inhibitors
Avoid concomitant use. If unavoidable, monitor potassium and blood pressure more frequently.
Other Mineralocorticoid Receptor Antagonists (MRAs)
Avoid concomitant use due to increased risk of hyperkalemia.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Overdose may cause hypotension and hyperkalemia. Treatment should be supportive and symptomatic. Hemodialysis is not expected to effectively remove finerenone.
Pregnancy & Lactation
Not recommended during pregnancy due to potential risks to the fetus. It is unknown if finerenone is excreted in human milk; avoid use during lactation.
Side Effects
Contraindications
- Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir)
- Adrenal insufficiency
Drug Interactions
Strong CYP3A4 Inducers
Avoid concomitant use due to significantly decreased finerenone exposure, reducing efficacy.
Strong CYP3A4 Inhibitors
Concomitant use is contraindicated due to significantly increased finerenone exposure and risk of hyperkalemia.
Moderate CYP3A4 Inhibitors
Avoid concomitant use. If unavoidable, monitor potassium and blood pressure more frequently.
Other Mineralocorticoid Receptor Antagonists (MRAs)
Avoid concomitant use due to increased risk of hyperkalemia.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Overdose may cause hypotension and hyperkalemia. Treatment should be supportive and symptomatic. Hemodialysis is not expected to effectively remove finerenone.
Pregnancy & Lactation
Not recommended during pregnancy due to potential risks to the fetus. It is unknown if finerenone is excreted in human milk; avoid use during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patented
Clinical Trials
Finerenone has been studied in large Phase 3 clinical trials, including FIDELIO-DKD and FIGARO-DKD, which demonstrated its efficacy in reducing cardiovascular and renal events in patients with CKD and type 2 diabetes.
Lab Monitoring
- Serum potassium levels (before treatment, 4 weeks after initiation/dose adjustment, and periodically thereafter)
- eGFR (before treatment, 4 weeks after initiation/dose adjustment, and periodically thereafter)
- Blood pressure
Doctor Notes
- Crucial to monitor serum potassium and eGFR before and during treatment.
- Avoid concomitant use with strong CYP3A4 inhibitors due to hyperkalemia risk.
- Educate patients on symptoms of hyperkalemia and importance of adherence.
Patient Guidelines
- Take Renaliv exactly as prescribed by your doctor.
- Do not stop taking Renaliv without consulting your doctor.
- Report any symptoms of hyperkalemia (e.g., muscle weakness, irregular heartbeat) to your doctor immediately.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take a double dose to make up for a missed one.
Driving Precautions
Renaliv may cause dizziness in some patients. Use caution when driving or operating machinery until you know how this medicine affects you.
Lifestyle Advice
- Follow a low-potassium diet as advised by your doctor or dietitian.
- Maintain good blood sugar control for managing type 2 diabetes.
- Engage in regular physical activity.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.